Aurinia Pharmaceuticals Inc. (AUPH) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
AUPH Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Aurinia Pharmaceuticals Inc. (AUPH) trades at a price-to-earnings ratio of 7.3x, with a stock price of $15.14 and trailing twelve-month earnings per share of $2.07.
The current P/E is 87% below its 5-year average of 56.3x. Over the past five years, AUPH's P/E has ranged from a low of 7.7x to a high of 204.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, AUPH trades at a 67% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, AUPH trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AUPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AUPH P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 25.3 | - | +419%Best | |
| $5B | 62.3 | - | -33% | |
| $102B | 6.7Lowest | 0.47Best | +348% | |
| $28B | 21.7 | - | -21% | |
| $39B | 127.0 | - | +207% | |
| $30B | 22.8 | 0.56 | +5% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
AUPH Historical P/E Data (2024–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $15.95 | $2.07 | 7.7x | -86% |
| FY2025 Q3 | $11.05 | $0.55 | 20.1x | -64% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $8.47 | $0.42 | 20.2x | -64% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $8.04 | $0.28 | 28.9x | -49% |
| FY2024 Q4 | $8.98 | $0.04 | 204.6x | +263% |
Average P/E for displayed period: 56.3x
See AUPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AUPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AUPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAUPH — Frequently Asked Questions
Quick answers to the most common questions about buying AUPH stock.
Is AUPH stock overvalued or undervalued?
AUPH trades at 7.3x P/E, below its 5-year average of 56.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does AUPH's valuation compare to peers?
Aurinia Pharmaceuticals Inc. P/E of 7.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is AUPH's PEG ratio?
AUPH PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.